EF Hutton Initiates Coverage On NRX Pharmaceuticals with Buy Rating, Announces Price Target of $31
Portfolio Pulse from Benzinga Newsdesk
EF Hutton has initiated coverage on NRX Pharmaceuticals with a Buy rating and set a price target of $31, indicating a positive outlook for the company's stock.
October 21, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has initiated coverage on NRX Pharmaceuticals with a Buy rating and a price target of $31, suggesting a positive short-term outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $31 by EF Hutton is likely to positively influence investor sentiment and drive the stock price up in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100